Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro

Abstract Complement-dependent cytotoxicity (CDC) is a primary mechanism-of-action of monoclonal antibody (mAb) immunotherapies used to treat haematological cancers, including rituximab and daratumumab. However, mAb efficacy may be limited by reduced bioavailability of complement C1q – which activate...

Full beskrivning

Bibliografiska uppgifter

Huvudupphov:	Harrison D. Collier-Bain, Frankie F. Brown, Adam J. Causer, Lois Ross, Daniela Rothschild-Rodriguez, Noah Browne, Rachel Eddy, Kirstie L. Cleary, Juliet C. Gray, Mark S. Cragg, Sally Moore, James Murray, James E. Turner, John P. Campbell
Materialtyp:	Artigo
Språk:	Inglês
Utgiven:	Nature Portfolio 2024-11-01
Serie:	Scientific Reports
Ämnen:	Complement-dependent cytotoxicity Immunotherapy Exercise Muscle damage Complement C1q
Länkar:	https://doi.org/10.1038/s41598-024-79690-8
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!